Sulfonamide Derivatives : Recent Compounds with Potent Anti- Alzheimer's Disease Activity
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Facile synthetic procedures and broad spectrum of biological activities are special attributes of sulfonamides. Sulfonamide derivatives have demonstrated potential as a class of compounds for the treatment of Alzheimer's disease (AD). Recent sulfonamide derivatives have been reported as prospective anti-AD agents, with a focus on analogues that significantly inhibit the function of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes and exhibit remarkable antioxidant and anti-inflammatory properties, all of which are critical for the treatment of AD. Sulfonamide- mediated activation of nuclear factor erythroid 2-related factor 2 (NRF2), a key regulator of the endogenous antioxidant response, has also been suggested as a potential therapeutic approach in AD. Additionally, it has been discovered that a number of sulfonamide derivatives show selectivity for the β- and γ-secretase enzymes and a significant reduction of amyloid B (Aβ) aggregation, which have been implicated in AD. The comparative molecular docking of benzenesulfonamide and donepezil, an AD reference drug showed comparable anti-AD activities. These suggest that sulfonamide derivatives may represent a new class of drugs for the treatment of AD. Thus, the current review will focus on recent studies on the chemical synthesis and evaluation of the anti-AD properties, molecular docking, pharmacological profile, and structure-activity relationship (SAR) of sulfonamide derivatives, as well as their potential anti-AD mechanisms of action. This paper offers a thorough assessment of the state of the art in this field of study and emphasizes the potential of sulfonamide derivatives synthesized during the 2012-2023 period as a new class of compounds for the treatment of AD.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Central nervous system agents in medicinal chemistry - (2024) vom: 24. Jan. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Egbujor, Melford Chuka [VerfasserIn] |
---|
Links: |
---|
Themen: |
Alzheimer disease |
---|
Anmerkungen: |
Date Revised 26.01.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.2174/0118715249278489231128042135 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367654865 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM367654865 | ||
003 | DE-627 | ||
005 | 20240126232334.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240126s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/0118715249278489231128042135 |2 doi | |
028 | 5 | 2 | |a pubmed24n1271.xml |
035 | |a (DE-627)NLM367654865 | ||
035 | |a (NLM)38275073 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Egbujor, Melford Chuka |e verfasserin |4 aut | |
245 | 1 | 0 | |a Sulfonamide Derivatives |b Recent Compounds with Potent Anti- Alzheimer's Disease Activity |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 26.01.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a Facile synthetic procedures and broad spectrum of biological activities are special attributes of sulfonamides. Sulfonamide derivatives have demonstrated potential as a class of compounds for the treatment of Alzheimer's disease (AD). Recent sulfonamide derivatives have been reported as prospective anti-AD agents, with a focus on analogues that significantly inhibit the function of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes and exhibit remarkable antioxidant and anti-inflammatory properties, all of which are critical for the treatment of AD. Sulfonamide- mediated activation of nuclear factor erythroid 2-related factor 2 (NRF2), a key regulator of the endogenous antioxidant response, has also been suggested as a potential therapeutic approach in AD. Additionally, it has been discovered that a number of sulfonamide derivatives show selectivity for the β- and γ-secretase enzymes and a significant reduction of amyloid B (Aβ) aggregation, which have been implicated in AD. The comparative molecular docking of benzenesulfonamide and donepezil, an AD reference drug showed comparable anti-AD activities. These suggest that sulfonamide derivatives may represent a new class of drugs for the treatment of AD. Thus, the current review will focus on recent studies on the chemical synthesis and evaluation of the anti-AD properties, molecular docking, pharmacological profile, and structure-activity relationship (SAR) of sulfonamide derivatives, as well as their potential anti-AD mechanisms of action. This paper offers a thorough assessment of the state of the art in this field of study and emphasizes the potential of sulfonamide derivatives synthesized during the 2012-2023 period as a new class of compounds for the treatment of AD | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Alzheimer disease | |
650 | 4 | |a Sulfonamide derivatives | |
650 | 4 | |a molecular docking. | |
650 | 4 | |a structure-activity relationship | |
773 | 0 | 8 | |i Enthalten in |t Central nervous system agents in medicinal chemistry |d 2008 |g (2024) vom: 24. Jan. |w (DE-627)NLM185149960 |x 1875-6166 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:24 |g month:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/0118715249278489231128042135 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 24 |c 01 |